The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.
 
Shanshan Wang
No Relationships to Disclose
 
Cheng Fu
No Relationships to Disclose
 
Qing Zou
No Relationships to Disclose
 
Youyuan Li
No Relationships to Disclose
 
Dalin He
No Relationships to Disclose
 
Shaogang Wang
No Relationships to Disclose
 
Hongkai Wang
No Relationships to Disclose
 
Matthew Raymond Smith
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst)
 
Bertrand F. Tombal
Honoraria - AAA/Endocyte/Novartis; Amgen; Astellas Pharma; AstraZeneca; Bayer; Ferring; Janssen; MSD Oncology; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen; Myovant Sciences; Pfizer/Astellas; Sanofi; Steba Biotech; Takeda
Speakers' Bureau - Amgen; Astellas Pharma; Astellas Pharma; Janssen
Research Funding - Ferring (Inst)
Expert Testimony - Steba Biotech
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Ferring; Janssen; Sanofi
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Yi Niu
Employment - Bayer HealthCare Pharmacuticals
 
Ling Cai
Employment - Bayer HealthCare Pharmacuticals
 
Nan Hu
Employment - Bayer Health
 
Shiyun Huang
Employment - Bayer HealthCare Pharmacuticals
 
Shivani Kapur
Employment - Bayer HealthCare Pharmacuticals
 
Rui Li
Employment - Bayer HealthCare Pharmacuticals
 
Iris Kuss
Employment - Bayer Germany
Stock and Other Ownership Interests - Bayer; Bayer
 
Dingwei Ye
No Relationships to Disclose